Trial Profile
Pharmacokinetics of Regorafenib by endogenous cortisol 6beta-hydroxylation clearance and potential of personalized use
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2019
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer; Gastrointestinal cancer
- Focus Adverse reactions
- 29 Mar 2019 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2015 New trial record